Request an invite

Datroway: which tox species, and why?

datopotamab deruxtecan · Trop-2
Species
Rat (non-binding) and cynomolgus monkey (relevant); DXd payload in rat and monkey
“Though datopotamab deruxtecan did not bind rat Trop2 in an in vitro assay, the monkey is a pharmacologically relevant species considering datopotamab deruxtecan demonstrated similar binding to human and monkey Trop2.”
✓ VerifiedFDA multi-discipline review, p. 66Source ↗
Why that species
Similar binding to human and monkey Trop2; weak to no binding to mouse and rat Trop2
“Datopotamab deruxtecan bound to human and monkey Trop2 similarly in an ELISA-based assay but demonstrated weak to no binding to mouse and rat Trop2.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Surrogate molecule
No surrogate; clinical ADC in rat and monkey; DXd payload in GLP 1-month rat and monkey studies
“The toxicity of DXd was also evaluated in GLP-compliant 1-month repeat-dose toxicology studies in rats and monkeys.”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗

Same question, other ADCs

Adcetris

brentuximab vedotin · CD30
Rat and cynomolgus monkey (monkey the antigen-binding species)

Besponsa

inotuzumab ozogamicin · CD22
Rat and cynomolgus monkey (neither cross-reactive; target-independent toxicity only)

Decnupaz

pivekimab sunirine · CD123
Cynomolgus monkey (no CD123 cross-reactivity; off-target/payload toxicity) plus rat for FGN849 payload

Elahere

mirvetuximab soravtansine · FRα
Cynomolgus monkey (general tox); rabbit for ocular tox; DM4 payload in monkey and mouse

Emrelis

telisotuzumab vedotin · c-Met
Cynomolgus monkey (relevant); rat non-binding (exploratory, MMAE-related effects)

Enhertu

fam-trastuzumab deruxtecan · HER2
Cynomolgus monkey (relevant) plus rat (non-binding species)

Kadcyla

ado-trastuzumab emtansine · HER2
Rat and cynomolgus monkey (monkey pharmacologically relevant; long-term studies in monkey)

Mylotarg

gemtuzumab ozogamicin · CD33
Rat and cynomolgus monkey (neither pharmacologically relevant; no CD33 cross-reactivity)

Padcev

enfortumab vedotin · Nectin-4
Rat and cynomolgus monkey

Polivy

polatuzumab vedotin · CD79b
Rat and cynomolgus monkey (monkey with clinical ADC plus monkey-CD79b surrogate ADC)

Tivdak

tisotumab vedotin · Tissue factor
Cynomolgus monkey only for ADC; rat and monkey for MMAE payload

Trodelvy

sacituzumab govitecan · Trop-2
Cynomolgus monkey only (mouse for target-independent toxicity only)

Zynlonta

loncastuximab tesirine · CD19
No pharmacologically relevant species; cynomolgus monkey (non-binding) for ADC; rat and dog for payload SG3199

Summary across all 14 ADCs →